浅谈基因治疗的现状及其面临的困境

基因治疗将在未来的疾病治疗中扮演重要的角色，然而这一新颖的技术却面临着诸多问题，本文论述了基因治疗的发展现状及其所面临的技术难题。     

王霞芳治疗小儿泄泻的经验

小儿泄泻的病因病机因其自身稚阴稚阳的生理特点而较成人为多发,泄泻久甚,易耗伤气液,甚至出现伤阴伤阳的重证、变证。故要重视及时正确地治疗,以防产生危候。王霞芳老师治疗小儿泄泻首先注重审证求因,在精确辨证基础上立法选方而施治,并在病变过程中法随症变,灵活化裁,刻刻护卫脾气胃津,斡旋脾胃气机,重视清浊升降枢机作用。尝用葛根、扁豆衣、荷叶等轻灵升清之品,宣发清阳,泄泻自和。对屡治不愈、迁延日久者,王师认为应辨证细致,选药精到,且又及时而适当地参入止涩药物。固肠止涩法之运用,必须具备苔净,腹软,溲通,无表证和里积等条件,方为合宜。     

PRENATAL DIAGNOSIS Ⅰ. EARLY DIAGNOSIS OF OPEN NEURAL TUBE DEFECTS BY QUALITATIVE ACETYLCHOLINESTERASE ISOENZYME IN AMNIOTIC FLUID

The measurement of amniotic fluid (AF) acetylcholinesterase isoenzyme (AChEI) is a relatively new method for early diagnosis of open neural tube defects (NTDs). As quantitative methods are of unproven reliability at present, the authors used a high resolving power qualitative method-vertical slab polyaerylamide gel electrophoresis. The benefits of this technique are: simplicity of operation, accuracy, unsophisticated equipment, and easily available reagents. Combined results of 9 NTDs studies revealed that samples from early pregnancy gave more accurate results than those from late pregnancy.     

Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility

Development of a disease screening biomarker involves several phases. In phase 2 its sensitivity and specificity is compared with established thresholds for minimally acceptable performance. Since we anticipate that most candidate markers will not prove to be useful and availability of specimens and funding is limited, early termination of a study is appropriate, if accumulating data indicate that the marker is inadequate. Yet, for markers that complete phase 2, we seek estimates of sensitivity and specificity to proceed with the design of subsequent phase 3 studies. We suggest early stopping criteria and estimation procedures that adjust for bias caused by the early termination option. An important aspect of our approach is to focus on properties of estimates conditional on reaching full study enrollment. We propose the conditional‐UMVUE and contrast it with other estimates, including naïve estimators, the well‐studied unconditional‐UMVUE and the mean and median Whitehead‐adjusted estimators. The conditional‐UMVUE appears to be a very good choice. Copyright © 2008 John Wiley & Sons, Ltd.     

新医改促动中国医疗器械市场竞争——CMEF 2009深圳见闻

编者按:第61届中国国际医疗器械博览会(简称医博会或CMEF)、第8届中国国际医疗器械设计与制造技术展览会(简称ICMD)于4月18～21日在深圳举行.本届CMEF设置标准展位5100多个,展出面积110000m2,参展企业2100余家,观众120000人次,36家国内展团、17家国家展团.除了原已开辟的医学影像区(CMEF Imaging)、体外诊断区(CMEF IVD)、医用电子仪器区、医用光学仪器区、医院设备区和医疗软技术(Medisoft)等专业分区以外,本届CMEF IT展区作为CMEF中新的专业分区,浓缩了医院信息化产业的发展进程,集中展示了医院信息化领域的最新技术.伴随新医改方案的出台,本次医博会弥漫着新一轮市场搏杀的硝烟.     

BKV in Simultaneous Pancreas-Kidney Transplant Recipients: A Leading Cause of Renal Graft Loss in First 2 Years Post-Transplant

With the introduction of more potent immunosuppressive agents, rejection has decreased in simultaneous pancreas/kidney transplant (SPK) recipients. However, as a consequence, opportunistic infections have increased. The purpose of this report is to outline the course of SPK patients who developed polyomavirus-associated nephropathy (PVAN). A retrospective review of 146 consecutive SPK recipients from January 1, 1996 to December 31, 2002 was performed. Immunosuppression, rejection and development of PVAN were reviewed. Nine patients were identified. All received induction with either OKT3 or thymoglobulin. Immunosuppression included tacrolimus/cyclosporine, MMF/azathioprine and sirolimus/prednisone. Two patients were treated for kidney rejection prior to the diagnosis of PVAN. Time to diagnosis was an average of 359.3 days post-transplantation. Immunosuppression was decreased but five ultimately lost function. However, none developed pancreatic abnormalities as demonstrated by normal glucose and amylase. Two underwent renal retransplantation after PVAN diagnosis and both have normal kidney function. PVAN was the leading cause of renal loss in SPK patients in the first 2 years after transplantation and is a serious concern for SPK recipients. The pancreas, however, is spared from evidence of infection, and no pancreatic rejection occurred when immunosuppression was decreased.